Greenville, NORTH%20CAROLINA2 Active Studies

Idiopathic Thrombocytopenic Purpura Clinical Trials in Greenville, NORTH%20CAROLINA

Find 2 actively recruiting idiopathic thrombocytopenic purpura clinical trials in Greenville, NORTH%20CAROLINA. Connect with local research sites and explore new treatment options.

2
Active Trials
2
Sponsors
211
Enrolling

Recruiting Idiopathic Thrombocytopenic Purpura Studies in Greenville

About Idiopathic Thrombocytopenic Purpura Clinical Trials in Greenville

Immune thrombocytopenia (ITP) is an autoimmune condition where the immune system destroys platelets, leading to easy bruising and bleeding. It can occur in children (often self-limiting) or adults (often chronic). Treatment includes corticosteroids, thrombopoietin receptor agonists, and rituximab.

There are currently 2 idiopathic thrombocytopenic purpura clinical trials recruiting participants in Greenville, NORTH%20CAROLINA. These studies are seeking a combined 211 participants. Research is being sponsored by Takeda, Kedrion S.p.A.. Clinical trial participation is free and participants receive study-related medical care at no cost.

Idiopathic Thrombocytopenic Purpura Clinical Trials in Greenville — FAQ

Are there idiopathic thrombocytopenic purpura clinical trials in Greenville?

Yes, there are 2 idiopathic thrombocytopenic purpura clinical trials currently recruiting in Greenville, NORTH%20CAROLINA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Greenville?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Greenville research site will contact you about next steps.

Are clinical trials in Greenville free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Greenville studies also compensate for your time and travel.

What idiopathic thrombocytopenic purpura treatments are being tested?

The 2 active trials in Greenville are testing new therapies including novel drugs, biologics, and treatment approaches for idiopathic thrombocytopenic purpura.

Data updated March 2, 2026 from ClinicalTrials.gov